CDMO DPT Laboratories, a specialist in semi-solid and liquid dosage forms, announced that it has implemented a high-speed bottle-filling center at its San Antonio location.
CDMO DPT Laboratories, a specialist in semi-solid and liquid dosage forms, announced that it has implemented a high-speed bottle-filling center at its San Antonio location.
The San Antonio site, which is one of three DPT Centers of Excellence, has been built to support the manufacturing of pharmaceutical semi-solids and liquids The new high-speed bottle-filling center provides large-scale production capacity and maximizes efficiency.
According to the company’s press release, DPT’s new line significantly increases the rate of production for finished goods bottle manufacturing up to 200 units per minute, and creates opportunities for growth in its large scale bulk manufacturing areas. With increased throughput capability, DPT now has the opportunity to provide bright stock supply chain services to clients seeking an external solution to their private label manufacturing needs.
DPT’s San Antonio site provides cGMP pilot, clinical and commercial-scale manufacturing for prescription and over-the-counter products. It includes a 60,000-square-foot cGMP aerosol manufacturing facility, a 225,000-square-foot raw material dispensing and distribution center and a 150,000-square-foot compounding, fill and finish area.
Source: DPT Laboratories
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.